Table 1.

Description of the model parameters with their values (ranges) for the GP and the HCWs (Salgado et al. 2002; Bridges et al. 2003; Ferguson et al. 2003, 2005; Horcajada et al. 2003; Longini et al. 2004, 2005; Gani et al. 2005; Low & Wilder-Smith 2005; Arino et al. 2006; Jefferson et al. 2006).

parameter	description	value (range)
c1	clinical attack rate in the GP	25–35%
c2	clinical attack rate among HCWs	25–50%
1/μE	incubation period	1.25 days
1/μP	infectious period of pre-symptomatic case	0.25 day
1/μI	infectious period of symptomatic case (stage 1)	1 day
1/μU	infectious period of untreated symptomatic case (stage 2)	2.85 days
1/μT	infectious period of treated symptomatic case	1.35 days
1/μA	infectious period of asymptomatic case	4.1 days
dU	death rate of untreated symptomatic infection	0.002 d−1
dT	death rate of treated symptomatic infection	0.001 d−1
δP	reduction in infectiousness of pre-symptomatic case	0.286
δA	reduction in infectiousness of asymptomatic case	0.071
δU	reduction in infectiousness of untreated symptomatic case	0.143
δT	reduction in infectiousness of treated symptomatic case	60%
αS	reduction in susceptibility due to prophylaxis	25–35%
αP	reduction in infectiousness due to prophylaxis	60%
p	probability of developing symptoms without prophylaxis	0.67
pP	probability of developing symptoms with prophylaxis	0.35